A plain language summary of results from the NeoADAURA study: treatment with osimertinib before surgery for patients with EGFR-mutated non-small cell lung cancer that can be surgically removed

Plain Language SummaryWhat is this summary about?Osimertinib is an oral (by mouth) medicine that blocks the mutated form of a protein called EGFR on cancer cells, reducing their growth and spread.Osimertinib is recommended for EGFR-mutated non-small cell lung cancer (NSCLC) after surgery, but its benefit before surgery was unclear.The Phase 3 NeoADAURA study examined whether osimertinib alone, or with chemotherapy, before surgery improved outcomes for patients with EGFR-mutated stage 2–3B non-small cell lung cancer.What were the results?358 patients were randomly assigned to receive either osimertinib plus chemotherapy, osimertinib alone, or placebo plus chemotherapy. Most patients underwent surgery: more than 90% of those who had surgery had all the cancer removed.The main result that this study looked at was major pathological response, which is defined as when 10% or fewer live cancer cells can be seen in tissue that is removed during surgery. Among all randomized patients, the proportion of patients achieving a major pathological response was: 26% with osimertinib plus chemotherapy25% with osimertinib alone2% with placebo plus chemotherapy.After 1 year, among all randomized patients, 93% who received osimertinib plus chemotherapy, 95% of those receiving osimertinib alone, and 83% receiving placebo plus chemotherapy did not experience cancer worsening or the disease coming back and remained alive. No unexpected safety issues were found.What do the results of the study mean?In people living with stage 2–3B, EGFR-mutated non-small cell lung cancer that can be surgically removed, osimertinib treatment with or without chemotherapy before surgery, worked better than placebo plus chemotherapy at reducing the amount of cancer at the time of surgery.Clinical trial number: NCT04351555

Authors

Institutions

Publication Details

Journal
Future Oncology
Published
2026-10-29
DOI
https://doi.org/10.1080/14796694.2026.2739188
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A plain language summary of results from the NeoADAURA study: treatment with osimertinib before surgery for patients with EGFR-mutated non-small cell lung cancer that can be surgically removed

Ligang Xing, Alex Martínez‐Martí, Collin Michael Blakely, Shuji Murakami et al.
3 links
Future Oncology
Lung Cancer Treatments and Mutations
article

A plain language summary of results from the NeoADAURA study: treatment with osimertinib before surgery for patients with EGFR-mutated non-small cell lung cancer that can be surgically removed

Ligang Xing, Alex Martínez‐Martí, Collin Michael Blakely, Shuji Murakami, Yuri Rukazenkov, Walter Weder, Somcharoen Saeteng, Maria Paz Saavedra, Carles Escriu, Yasushi Yatabe, Jamie E. Chaft, Sanja Đačić, Jin-Yuan Shih, Sung Yong Lee, Anupriya Dayal, Viet Nhung Nguyen, Carlos Henrique Andrade Teixeira, Jianxing He, Xiangning Huang, Hochmair Maximilian J., for the NeoADAURA Investigators, Lunxu Liu, Ke-Neng Chen, Nguyen Hoang Gia, Seong Hoon Yoon, Yongtao Han, Kang-Yun Lee
article en

Abstract

Plain Language SummaryWhat is this summary about?Osimertinib is an oral (by mouth) medicine that blocks the mutated form of a protein called EGFR on cancer cells, reducing their growth and spread.Osimertinib is recommended for EGFR-mutated non-small cell lung cancer (NSCLC) after surgery, but its benefit before surgery was unclear.The Phase 3 NeoADAURA study examined whether osimertinib alone, or with chemotherapy, before surgery improved outcomes for patients with EGFR-mutated stage 2–3B non-small cell lung cancer.What were the results?358 patients were randomly assigned to receive either osimertinib plus chemotherapy, osimertinib alone, or placebo plus chemotherapy. Most patients underwent surgery: more than 90% of those who had surgery had all the cancer removed.The main result that this study looked at was major pathological response, which is defined as when 10% or fewer live cancer cells can be seen in tissue that is removed during surgery. Among all randomized patients, the proportion of patients achieving a major pathological response was: 26% with osimertinib plus chemotherapy25% with osimertinib alone2% with placebo plus chemotherapy.After 1 year, among all randomized patients, 93% who received osimertinib plus chemotherapy, 95% of those receiving osimertinib alone, and 83% receiving placebo plus chemotherapy did not experience cancer worsening or the disease coming back and remained alive. No unexpected safety issues were found.What do the results of the study mean?In people living with stage 2–3B, EGFR-mutated non-small cell lung cancer that can be surgically removed, osimertinib treatment with or without chemotherapy before surgery, worked better than placebo plus chemotherapy at reducing the amount of cancer at the time of surgery.Clinical trial number: NCT04351555

Future Oncology
AstraZeneca (United Kingdom) (GB), Memorial Sloan Kettering Cancer Center (US), University of Liverpool (GB), University of Electronic Science and Technology of China (CN), Vietnam National University, Hanoi (VN), University of California, San Francisco (US), University of Zurich (CH), Cornell University (US), Korea University Medical Center (KR), Clatterbridge Cancer Centre NHS Foundation Trust (GB), Yale University (US), National Cancer Centre Japan (JP), West China Hospital of Sichuan University (CN), Peking University Cancer Hospital (CN), Hospital Alemão Oswaldo Cruz (BR), First Affiliated Hospital of Guangzhou Medical University (CN), Shandong Tumor Hospital (CN), Sichuan Cancer Hospital (CN), Vall d'Hebron Hospital Universitari (ES), National Taiwan University Hospital (TW), Pusan National University Yangsan Hospital (KR), State Key Laboratory of Respiratory Disease (CN), Taipei Medical University-Shuang Ho Hospital (TW), Hanoi Lung Hospital (VN), Karl Landsteiner Society (AT), Institut für Lungenforschung (DE), Shandong First Medical University (CN), UCSF Helen Diller Family Comprehensive Cancer Center (US), Kanagawa Cancer Center (JP), Weill Cornell Medicine (US), Vall d'Hebron Institute of Oncology (ES), State Key Laboratory of Molecular Oncology (CN), Hanoi Oncology Hospital (VN), Korea University Guro Hospital (KR), Bệnh viện Phổi Trung ương (VN), Taipei Medical University (TW), Chiang Mai University (TH), Pusan National University (KR)
AstraZeneca
Good health and well-being
Openalex Percentile: Top 12%
Lung Cancer Treatments and Mutations
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon